A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale)
Introduction
Fibromyalgia (FM) and chronic fatigue syndrome (CFS) are both chronic clinical conditions characterised by a variety of nonspecific symptoms, including prominent fatigue, myalgia, and sleep disturbances. Despite different diagnostic criteria, CFS and FM have many demographic and clinical similarities with few differences in the domains of symptoms [1], [2]. Both disorders seek their clinical recognition and, so far, their diagnoses are based on criteria. There are no widely accepted pathogenic explanatory models for either illness [2], [3]. In spite of extensive research, treatment continues to be of limited success [4].
Treatment studies on FM/CFS have frequently used the Visual Analogue Scale (VAS) to obtain patient perception data. The profile of mood has been estimated using rating scales for depression such as the Hamilton Depression Rating Scale [5] and the Beck Depression Inventory [6]. The Arthritis Impact Measurement Scales [7] and the Fibromyalgia Impact Questionnaire (FIQ) [8] are self-rating instruments which have been used to assess functional limitations and disability. They have been evaluated for reliability and validity in the FM population [9]. Self-rating scales are also provided for the evaluation of fatigue [10], [11], [12] and one self-rating scale for screening CFS symptoms has been published [13]. In a previous trial on FM/CFS [14], we found the neurasthenia subscale of the Comprehensive Psychopathological Rating Scale (CPRS) [15], [16] useful for evaluation of treatment effects.
Within psychiatry, observer's rating scales are often considered more valid and reliable than self-rating scales. In this study, we wanted to construct a new observer's rating scale aimed at the assessment of core symptoms and treatment outcome in FM and CFS. Due to substantial overlap in symptomatology between FM and CFS, we decided to develop a scale suitable for both conditions. The scale should be based on the CPRS items that we had used within a double-blind treatment study and their psychometric properties be tested against global rating scales [17] and the FIQ.
Section snippets
Patients
The present study was based on a group of 100 patients, all women, aged 20–66 years [mean 47.8 years (±11.1 S.D.)] who were evaluated in a 24-week double-blind clinical trial. In the trial, patients were given repeated subcutaneous injections of a staphylococcus toxoid vaccine or placebo [18]. To be included in the research program, the patients had to fulfil the American College of Rheumatology (ACR) criteria for FM [19] and the 1994 criteria for CFS established by the CDC [20]. The patients
Primary item selection for the new scale
Of the 15 CPRS items used both in a previous [14] and in the present study, we wanted to exclude those that did not occur sufficiently often to be regarded as core symptoms and those that received so low scores that changes would be difficult to register (floor effect). The baseline frequencies of scores above zero on the 15 items were therefore calculated and ranked by incidence. An arbitrary cutoff point of 70% occurrence was used to identify the most common items in the total sample of
Primary item selection for the FibroFatigue scale
One hundred patients were evaluated at baseline. For 90 of them, CPRS scores, as well as scores on the FIQ and the global scales, were available from ratings before and after 24 weeks of treatment. Six of the 15 CPRS items were found to have a baseline incidence below 70%. The mean scores on these items were also low (Table 1). For these reasons, they were excluded from further analysis. Thus, nine items remained for evaluation. These were: “aches and pain,” “fatiguability,” “reduced sleep,”
Discussion
To our knowledge, there is no observer's rating scale available that is specifically designed for FM or CFS. Despite different diagnostic criteria, these two conditions have many demographic and clinical similarities [1], [2]. They are both characterised by a variety of nonspecific symptoms, including prominent fatigue, myalgia, and sleep disturbances. Up to 70% of patients with CFS-like illnesses may have concurrent FM [29] and it may be of little importance to differentiate them [30]. On the
Acknowledgements
Thanks to Mrs Ingrid Larsson for language revision and linguistic advice.
References (37)
Fibromyalgia and chronic fatigue syndrome: similarities and differences
Rheum Dis Clin North Am
(1996)- et al.
Development of a fatigue scale
J Psychosom Res
(1993) - et al.
The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue
J Psychosom Res
(1995) - et al.
Effects of staphylococcus toxoid vaccine on pain and fatigue in patients with fibromyalgia/chronic fatigue syndrome
Eur J Pain
(1998) - et al.
Construction of a new psychiatric rating instrument, the Comprehensive Psychopathological Rating Scale (CPRS)
Prog Neuro-Psychopharmacol
(1979) Reliability and validity studies of the Comprehensive Psychopathological Rating Scale (CPRS)
Prog Neuro-Psychopharmacol
(1979)- et al.
Functional somatic syndromes: one or many?
Lancet
(1999) - et al.
Comorbidity of fibromyalgia with medical and psychiatric disorders
Am J Med
(1992) - et al.
Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities
Arch Intern Med
(1994) Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome
Curr Opin Rheumatol
(1994)
Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome
Curr Opin Rheumatol
Development of a rating scale for primary depressive illness
Br J Soc Clin Psychol
Assessment of depression: the Depression Inventory
Mod Probl Pharmacopsychiatry
Measuring health status in arthritis. The Arthritis Impact Measurement Scales
Arthritis Rheum
The Fibromyalgia Impact Questionnaire: development and validation
J Rheumatol
Assessment of functional limitation and disability in patients with fibromyalgia
Scand J Rheumatol
The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus
Arch Neurol
A screening scale for chronic fatigue syndrome: reliability and validity
J Chronic Fatigue Syndr
Cited by (156)
Neuronal damage and inflammatory biomarkers are associated with the affective and chronic fatigue-like symptoms due to end-stage renal disease
2024, Journal of Affective DisordersIntersections between pneumonia, lowered oxygen saturation percentage and immune activation mediate depression, anxiety, and chronic fatigue syndrome-like symptoms due to COVID-19: A nomothetic network approach
2022, Journal of Affective DisordersCitation Excerpt :The HAM-A subdomain scores were a) the key anxiety symptom domain (key HAM-A), namely the sum of anxious mood + tension + fears + anxious behavior at interview; and b) the HAM-A physiosomatic symptom domain (physiosomatic HAM-A), namely the sum of somatic muscular + somatic sensory + cardiovascular symptoms + gastrointestinal symptoms + genitourinary symptoms + autonomic symptoms (but not the respiratory symptoms). The same senior psychiatrist also assessed the Fibromyalgia and Chronic Fatigue Syndrome Rating (FF) scale (Zachrisson et al., 2002). This scale assesses 12 FF symptoms, namely FF1: muscle pain, FF2: muscular tension, FF3: fatigue, FF4: concentration difficulties, FF5: failing memory, FF6: irritability, FF7: sadness, FF8: sleep disturbances, FF9: autonomic disturbances, FF10: irritable bowel, FF11: headache, and FF12: a flu-like malaise.